Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE)

Hrudya Abraham, Jose Kuzhively, Syed W Rizvi, Hrudya Abraham, Jose Kuzhively, Syed W Rizvi

Abstract

BACKGROUND Chronic inflammatory demyelinating polyneuropathy (CIDP) is an uncommon manifestation of systemic lupus erythematosus (SLE). We report a case of SLE presenting as CIDP and discuss the diagnosis, management, and prognosis of CIDP. CASE REPORT A 40-year-old woman with a past medical history of SLE treated with hydroxychloroquine presented with bilateral, progressive, ascending, sensory and motor neuropathy. Physical examination showed weakness and reduced temperature of all extremities, reduced pinprick and vibration sense of the distal extremities, loss of reflexes, and walking with a wide-based unsteady gait. Laboratory investigations showed positive antinuclear antibodies (ANA), anti-(smooth muscle (SM) antibody, anti-RNP antibody, anti-SSA antibody, anti-ds-DNA antibody, and an erythrocyte sedimentation rate (ESR) of 75 mm/hr, low C4, leukopenia, and anemia. Electromyography (EMG) confirmed the diagnosis of CIDP. The patient's neuropathy and muscle weakness improved on treatment with intravenous immunoglobulin (IVIG) and high-dose steroids. CONCLUSIONS The early clinical diagnosis of CIDP, supported by serological autoantibody profiles associated with SLE, can predict a good response to steroids. Most patients with CIDP are treated successfully with steroids if the diagnosis is made early. IVIG, plasmapheresis, or immunosuppressive therapy should be considered if there is no response to steroids.

Conflict of interest statement

Conflict of interest: None declared

Conflict of interest

None.

References

    1. Vina ER, Fang AJ, Wallace DJ, et al. Chronic Inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: Prognosis and outcome. Semin Arthritis Rheum. 2005;35:175–84.
    1. Pollard JD. Chronic inflammatory demyelinating polyradiculopathy. Curr Opin Neurol. 2002;15:279–83.
    1. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: From bench to bedside. Semin Neurol. 2012;32:187–95.
    1. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–85.
    1. Stefurak TL, Midroni G, Bilbao JM. Vasculitic polyradiculopathy in systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 1999;66:658–61.
    1. Futrell N, Schultz LR, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology. 1992;42:1649–57.
    1. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: A study of 41 patients. Neurology. 2007;69:644–54.
    1. Kumar V, Kaur J, Pothuri P, et al. Atypical trigeminal neuralgia: A rare neurological manifestation of systemic lupus erythematosus. Am J Case Rep. 2017;18:42–45.
    1. Sedgwick RP, Von Hager KO. Neurologic manifestation of lupus erythematosus and periarteritis nodosa: Report of 10 cases. Bul LA Neuro Scc. 1948;13:129.
    1. Retchland E, Comblath DR, Stern BJ, et al. Chronic demyelinating polyneuropathy in systemic lupus erythematosus. Neurology. 1984;34:135–37.
    1. Kieseir BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating polyneuropathy. Neurology. 2002;59:S7–12.
    1. Tokyo KV, Gold F. The pathogenesis of CIDP; Rationale for treatment with immunomodulatory agents. Neurology. 2003;60:S2–7.
    1. Latov N. Diagnosis of CIDP. Neurology. 2002;59:S2–6.
    1. Misra UK, Kalita J, Nair P. Ann Indian Acad Neurol. 2008;11:89–97.
    1. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:617–18.
    1. Trojaborg W. Acute and chronic neuropathies: new aspects of Gillian-Barre syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and update. Electroencephalogram Clin Neurophysiol. 1998;107:303–16.
    1. Haq RU, Fries TJ, Pendlebury WW, et al. Chronic inflammatory demyelinating polyneuropathy – a study of proposed electrodiagnostic and histologic criteria. Arch Neurol. 2000;57:1745–50.
    1. Hanston P, Kevers L, Fabien N, et al. Acute onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve. 2010;59:423–26.
    1. Sindern E, Stark E, Hass J, et al. Serum antibodies to GM1 and GM3 gangliosides in systemic lupus erythematosus with chronic inflammatory demyelinating polyradiculoneuropathy. Acta Neurol Scand. 1991;83:399–402.
    1. Gupta D, Mohanty D, Thakral D, et al. Unusual association of hemophagocytic lymphohistiocytosis in systemic lupus erythematosus. Cases reported at tertiary care center. Am J Case Rep. 2016;17:739–44.
    1. Jasmin R, Sockalingam S, Shahrizaila N, et al. Successful treatment of chronic inflammatory demyelinating polyneuropathy in systemic lupus Erythematosus with oral cyclophosphamide. Lupus. 2012;21:1119–23.
    1. Zolio MA, Eduardo B, Enriquie F, et al. Chronic inflammatory demyelinating polyradiculopathy in a boy with systemic lupus Erythematosus. Rheumatol Int. 2010;30:965–68.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren